Develop an autologous haematopoietic stem cell‒based gene therapy within a multinational, multicentre clinical trial for treating RAG1-SCID.

Treat the patients with the developed RAG1-SCID gene therapy eliminating complications and increasing survival.

Make gene therapy a realistic option for > 70% of all SCID patients in Europe with reduced healthcare costs.